Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry

JACC. Cardiovascular Interventions
Soraya El GhannudiOlivier Morel

Abstract

The aim of this study was to determine whether low platelet response to the P2Y(12) receptor antagonist clopidogrel as assessed by Vasodilator-stimulated phosphoprotein flow cytometry test (VASP- FCT) predicts cardiovascular events in a high-risk population undergoing percutaneous coronary intervention (PCI). Impaired platelet responsiveness to clopidogrel is thought to be a determinant of cardiovascular events after PCI. The platelet VASP-FCT is a new assay specific to the P2Y(12) adenosine diphosphate receptor-pathway. In this test, platelet activation is expressed as platelet reactivity index (PRI). Four-hundred sixty-one unselected patients undergoing urgent (n = 346) or planned (n = 115) PCI were prospectively enrolled. Patients were classified as low-response (LR) and response (R) to clopidogrel, depending on their PRI. Optimal PRI cutoff was determined by receiver-operator characteristic curve analysis to 61% (LR: PRI > or =61% and R: PRI <61%). Follow-up was obtained at a mean of 9 +/- 2 months in 453 patients (98.3%). At follow-up, total cardiac mortality rates and possible and total stent thrombosis were higher in LR patients. Multivariate analysis identified creatinine clearance (hazard ratio [HR]: 0.95; 95% confiden...Continue Reading

References

Jun 25, 2003·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Paul BarraganMartin Eigenthaler
Dec 7, 2006·JAMA : the Journal of the American Medical Association·Eric L EisensteinRobert M Califf
Feb 14, 2007·The New England Journal of Medicine·Bo LagerqvistUNKNOWN SCAAR Study Group
Apr 11, 2007·The Journal of Pharmacology and Experimental Therapeutics·William A SchumacherRobert P Rehfuss
Oct 16, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Dec 8, 2007·Thrombosis and Haemostasis·Rüdiger BlindtRainer Hoffmann
Feb 7, 2008·JAMA : the Journal of the American Medical Association·P Michael HoJohn S Rumsfeld
Mar 11, 2008·Thrombosis and Haemostasis·Christian Gachet
Aug 23, 2008·Journal of the American College of Cardiology·Thomas CuissetJean Louis Bonnet
Oct 14, 2008·Journal of the American College of Cardiology·Lawrence AngEhtisham Mahmud
Apr 14, 2009·Current Atherosclerosis Reports·Ali J Marian
Dec 25, 2009·Circulation. Cardiovascular Interventions·Bo LagerqvistUNKNOWN Swedish Coronary Angiography and Angioplasty Registry Study Group

❮ Previous
Next ❯

Citations

Feb 22, 2013·Thrombosis and Haemostasis·M Cattaneo
Mar 1, 2012·Vascular Health and Risk Management·Rakesh K SharmaJames D Marsh
Mar 28, 2013·Cardiology Research and Practice·Adriana Dana Oprea, Wanda M Popescu
Mar 20, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Clotilde MullerOlivier Morel
Nov 22, 2014·Thrombosis and Haemostasis·D AradiUNKNOWN Working Group on Thrombosis of the European Society of Cardiology
Jan 26, 2012·Thrombosis and Haemostasis·Nora MalloukSilvy Laporte
Nov 16, 2010·Cardiovascular Therapeutics·Jean-Luc RenyPierre Fontana
Aug 25, 2012·Platelets·Paul Harrison
Nov 23, 2013·JACC. Cardiovascular Interventions·Jolanta M Siller-MatulaUNKNOWN EPA (European Platelet Academy)
May 21, 2015·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Chanjuan CuiJie Zhang
Feb 9, 2018·Journal of Atherosclerosis and Thrombosis·Jessica RistortoOlivier Morel
Mar 13, 2014·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Manne HolmJan van der Linden

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.